New cocktail of drugs takes on advanced lung cancer
NCT ID NCT07309276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of four drugs (JS212, JS207, Toripalimab, and JS213) in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 864 participants will receive the drugs by IV every three weeks. The trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JS212, JS207, Toripalimab, JS213 (drugs given by IV infusion every 21 days)
What this could lead to
If successful, this could offer a new combination treatment option to shrink tumors or slow disease progression in advanced lung cancer.
What could go wrong
This is an early-phase (Phase II) trial, so the combination may not work better than existing treatments. Side effects from the drug combination are possible and being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact